Nevertheless, our results warrant further clinical investigation of combining mutant p53 status and cavin-1 expression as another indicator for predicting outcome in resectable PDAC, since resection did not benefit those patients whose cancers overexpressed both molecules. The gene discussed is TP53; the disease is cancer.